CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞衔接的规则：CAR-T 细胞和双特异性抗体在 B 细胞淋巴瘤中的现状
英文原题：The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.
查看英文原题
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞衔接疗法改变了复发/难治性B细胞非霍奇金淋巴瘤的治疗格局，为过去治疗选择有限的患者提供了高效治疗。本综述聚焦嵌合抗原受体修饰T细胞和双特异性抗体的进展：首先概述各类产品，继而梳理目前可用产品在大B细胞淋巴瘤、滤泡性淋巴瘤及套细胞淋巴瘤中的主要数据。综述还强调不同疾病和产品类型在临床决策中需要考虑的关键物流安排及治疗顺序问题。
展开英文摘要原文
T-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options.
This review focuses on the advances in chimeric antigen receptor-modified T cells and bispecific antibodies, first providing an overview of each product type, followed by exploring the primary data for currently available products in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This review also highlights key logistical and sequencing considerations across diseases and product types that can affect clinical decision-making.
论文信息
- 作者
- Haydu JE、Abramson JS
- 单位
- Center for Lymphoma, Mass General Cancer Center, Boston, MA.United States
- 文献类型
- 综述
- 期刊
- Blood advances2024 Sep 10
- 原文标识
- PubMed 39042891 · DOI 10.1182/bloodadvances.2021004535
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →